Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria

Rare Pediatric Designation granted

MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy

HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation of a Phase II clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease.

Based on previous clinical experience from the 1st generation product, MNV-101 (autologous hematopoietic stem cell product augmented with syngeneic maternal mitochondria), Minovia designed this phase II study with change in growth (height SDS) as primary endpoint. According to the natural history study recently published by Dr. Rebecca Ganetzky from CHOP, all patients with Pearson Syndrome suffer from failure to thrive and do not respond to growth hormone. Natural history shows an annual reduction of 0.5 units in height SDS, while MNV-101 treated patients showed stabilization or improvement, with no decline of height SDS at the 6 and 12 month follow up time points in a comparable subset of patients. This change in growth correlated with an improved International Pediatric Mitochondrial Disease Scale (IPMDS), which measures how the patient feels and functions (R2=0.9; p=0.0036). Linear growth was also suggested as an objective and clinically meaningful endpoint for a pivotal trial in Pearson by the FDA in early interactions.

“The FDA’s clearance of our IND marks an important achievement for Minovia, allowing us to clinically evaluate our allogeneic mitochondrial cell therapy approach and proceed with the Phase II clinical program for this first-in-class allogeneic mitochondrial therapy for Pearson Syndrome patients,” said Natalie Yivgi Ohana, PhD, CEO of Minovia. “We are pleased to have safely dosed three Pearson patients enrolled in an ongoing study under the Israeli Ministry of Health. We look forward to treating additional patients under this IND, as well as to learning about the potential of MNV-201 to improve growth in this patient population.”

“We are pleased that our cumulative interactions with the FDA enabled alignment on requirements for the entire MNV-201 program, including preclinical, CMC, and clinical aspects,” said Noa Sher, PhD, CSO of Minovia. “Early clinical and regulatory experience with MNV-101 shaped the current program and enabled a successful IND submission.”

The Phase II clinical trial is an open-label, single dose study to evaluate the safety and efficacy of MNV-201 in pediatric subjects diagnosed with Pearson Syndrome. The trial will also enable assessment of efficacy in improving growth and quality of life. The study is expected to enroll three additional patients up to a total of 6 patients. For more information visit clinicaltirals.gov

About MNV-201
MNV-201 is an autologous hematopoietic stem cell product enriched with allogeneic mitochondria. MNV-201 aims to restore mitochondrial function in patient hematopoietic stem cells, resulting in improved differentiation and function. Preclinical research suggests the potential for safe dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for MNV-201 therapy.

About Pearson Syndrome
Pearson Syndrome is a multisystem progressive pediatric mitochondrial disease caused by single large-scale mitochondrial deletions (SLSMDS) of mitochondrial DNA (mtDNA), with consequent defects in the mitochondrial respiratory chain function. Pearson Syndrome classically presents in the first year of life with bone marrow failure and exocrine pancreatic dysfunction. Patients have macrocytic sideroblastic anemia that is frequently transfusion-dependent and may be accompanied by thrombocytopenia and neutropenia. Pancreatic dysfunction occurs secondary to fibrosis and leads to chronic diarrhea, malabsorption, and failure to thrive. Pearson Syndrome is marked by accumulating organ system involvement and worsening disease: variable other organ involvement can occur, including renal tubulopathy, liver cholestasis and/or fibrosis, adrenal insufficiency, diabetes mellitus, cardiomegaly, and/or cardiac conduction defects. Pearson Syndrome is universally fatal and since there is no effective therapy, the diagnosis of Pearson Syndrome is one of the worst diagnoses that a caregiver must deliver to parents of an affected infant. MNV-201 aims to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both lifespan and quality of life.

About Minovia Therapeutics
Minovia Therapeutics Ltd. is a clinical stage biotechnology company advancing mitochondrial therapies for primary-genetic and age-related mitochondrial diseases. Minovia's clinical stage product candidate, MNV-201, is composed of mobilized peripheral blood, autologous CD34+ cells enriched with allogeneic, cryopreserved placental derived mitochondria, produced by Minovia's proprietary Mitochondrial Augmentation Technology (MAT). The enrichment of hematopoietic stem cells with healthy and functional mitochondria aims to restore stem cells function of patients suffering mitochondrial dysfunction, caused both by mtDNA mutations or deletions in pediatric patients suffering from primary mitochondrial diseases, or in adults with age-related diseases. MNV-201 is currently in clinical studies for pediatric patients with single-large scale mtDNA deletion syndromes (Pearson Syndrome and Kearn Sayre Syndrome) with five patients successfully dosed; and in Low Risk Myelodysplastic Syndrome. For more information, please visit www.minoviatx.com or follow the Company LinkedIn.

Contact Information: Natalie Yivgi Ohana, Co-Founder and CEO

Phone: +972-74-7039954

Email: info@minoviatx.com


Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome


THỦ THUẬT HAY

Cách theo dõi trận chung kết AFF Cup 2018 lượt về giữa Việt Nam và Malaysia

Hòa vào không khí trận chung kết lượt về AFF Cup 2018 giữa Việt Nam và Malaysia diễn ra vào lúc 19h30p trên sân vận động Mỹ Đình, Tin Tức TCNShop sẽ hướng dẫn người hâm mộ cách theo dõi trận chung kết hoàn hảo, hấp dẫn

Hướng dẫn sử dụng VPN trên trình duyệt Opera

Cho đến nay, hầu hết các dịch vụ VPN và máy chủ proxy đều bị giới hạn và dựa trên đăng ký trả tiền. Với một VPN miễn phí, không giới hạn, mà chỉ hoạt động khi chưa có hộp thoại và không đòi hỏi bất kỳ đăng ký nào,

Nâng cấp mua tài khoản ChatGPT Plus (ChatGPT-4) chính chủ giá rẻ 2023

Sau màn đổ bộ xuất sắc của ChatGPT trên các nền tảng xã hội lớn, chắc hẳn bạn đã thấy những lợi ích tuyệt vời của công cụ AI tuyệt vời này trong công việc và cuộc sống hàng ngày rồi phải không? Hơn thế nữa, mới đây,

Cách quản lý hình ảnh trên iPhone bằng iPhone Photo Manager

iPhone Photo Manager là phần mềm quản lý hình ảnh trên iPhone, chuyển và xóa hình ảnh ngay trên máy tính.

Hướng dẫn cách tạo thẻ tín dụng ảo để đăng ký Spotify

Dịch vụ nghe nhạc trực tuyến Spotify mới chính thức ra mắt tại Việt Nam vào ngày 13/03 vừa qua với hai gói dịch vụ bao gồm Spotify Free và Spotify Premium. Với Spotify Premium cho phép bạn nghe nhạc chất lượng cao trực

ĐÁNH GIÁ NHANH

Đánh giá nhanh Samsung CHG90: màn hình siêu dài 49 triệu của Samsung

Tuy nhiên, nếu cần một không gian làm việc có thể gây ấn tượng cho người khác, hay cần một màn hình với kích cỡ và màu sắc phù hợp với game thủ thì rõ sàng CHG90 là một sản phẩm rất đáng chú ý.

Đánh giá nhanh OPPO F3 Lite: Bản rút gọn hoàn hảo của OPPO F3

OPPO F3 Lite hay còn được biết đến với tên gọi OPPO A57, là phiên bản rút gọn của OPPO F3, tiếp tục thừa hưởng khả năng selfie ấn tượng, thiết kế đẹp mắt, cấu hình khá và có giá bán hợp lý cho nhiều đối tượng người dùng

Đánh giá Acer Asprise F5 - 573 - 39Q0 Thiết kế sang trọng, thời lượng pin cao

Acer Aspire F5 là một chiếc laptop hội tụ 3 yếu tố: Thiết kế sang trọng – Hiệu năng ổn định – Giá cả phải chăng. Nó đủ sức gánh vác nhu cầu làm việc văn phòng cũng như giải trí khi căng thẳng. Dù trọng lượng còn lớn...